E3 PreliminaryPreliminaryPEM requiredCross-SectionalPeer-reviewedReviewed
Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis using the novel application of autoMACS magnetic separation and flow cytometry.
Balinas, Cassandra, Nguyen, Thao, Johnston, Samantha et al. · Asian Pacific journal of allergy and immunology · 2018 · DOI
Quick Summary
This study looked at immune cells called mast cells in people with ME/CFS, comparing them to people with a known mast cell disorder and healthy volunteers. Mast cells help the body fight viruses and allergies. The researchers found differences in how these cells behave when exposed to viral-like substances, suggesting mast cells may play a role in ME/CFS symptoms.
Why It Matters
Many ME/CFS patients report viral infection triggers and allergic-type symptoms; understanding mast cell dysfunction could explain these experiences and guide treatment development. This study provides a novel, less invasive method to study immune dysfunction in ME/CFS, potentially enabling future large-scale investigations.
Observed Findings
- Significant decrease in HLA-DR+/CD154- expression in ME/CFS participants compared to systemic mastocytosis participants both before and after viral stimulation.
- Increase in HLA-DR-/CD154+ expression in ME/CFS participants following Poly I:C stimulation.
- No significant differences in mast cell progenitor maturity markers between ME/CFS, systemic mastocytosis, and healthy control groups.
- No significant differences in CD2/CD25 expression (systemic mastocytosis-specific markers) between groups.
Inferred Conclusions
- Mast cell progenitors may be involved in ME/CFS pathophysiology, distinct from systemic mastocytosis.
- Altered immune interaction receptor expression in ME/CFS mast cells suggests an atypical immune response to viral-like stimuli.
- Further investigation is needed to determine the immunological role and clinical significance of these cellular changes.
Remaining Questions
- What is the functional consequence of altered HLA-DR and CD154 expression on mast cell activation and cytokine release in ME/CFS?
- Do these mast cell differences correlate with symptom severity or disease progression in ME/CFS patients?
- How do these findings translate to mast cell behavior in tissues (not just peripheral blood) relevant to ME/CFS symptoms?
What This Study Does Not Prove
This pilot study does not prove that mast cell dysfunction causes ME/CFS symptoms, nor does it establish the clinical significance of the observed molecular differences. The small sample size and lack of longitudinal follow-up mean findings may not represent the broader ME/CFS population or predict disease progression.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedSmall SampleExploratory Only
Phenotype:Infection-Triggered
Metadata
- DOI
- 10.12932/AP-200517-0086
- PMID
- 29223146
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.